Pfizer is actively integrating artificial intelligence (AI) across various facets of its operations, from drug development and clinical trials to supply chain management. By leveraging machine learning to enhance drug discovery, expediting clinical trials, and optimizing its supply chain, Pfizer has positioned itself as a leader in AI-driven healthcare innovation. As the company continues to expand its AI capabilities, the recent appointment of Berta Rodriguez-Hervas as Chief AI and Analytics Officer marks a significant step in further solidifying this leadership.
In her new role, she will not only oversee Pfizer’s AI and analytics operations but also serve as the Co-chair of the company’s AI Council, a role that highlights her importance in steering the company’s AI strategy forward.
Lidia Fonseca, Pfizer’s Chief Digital and Technology Officer and Executive Vice President, expressed her excitement about this addition to her team, stating in a LinkedIn post, “I am thrilled that Berta Rodriguez-Hervas has joined my Pfizer Digital leadership team as our Chief AI and Analytics Officer. She will also be the new Co-chair of Pfizer’s AI Council.” Fonseca’s words emphasize the high expectations placed on Rodriguez-Hervas to drive AI innovation within the organization.
Rodriguez-Hervas brings an impressive track record of rapidly developing and scaling AI solutions in large, global organizations. Before joining Pfizer, she served as Vice President of Artificial Intelligence, Algorithms, and Machine Learning Operations at Stellantis, where she was instrumental in shaping the strategy for the next generation of autonomous vehicles. Her extensive experience also includes key roles at NVIDIA and Tesla, where she led advanced programs in computer vision, deep learning, and autonomous driving.
In her LinkedIn announcement, Rodriguez-Hervas shared her enthusiasm for the role, noting, “I am incredibly inspired by the shared vision I have with Lidia Fonseca regarding the future of AI at Pfizer and the immense impact we will bring to patients’ lives. I can’t wait to build this future together with all Pfizer colleagues, partners, and future colleagues.” Her passion for innovation and patient-centered AI solutions aligns perfectly with Pfizer’s broader goals.
This leadership move comes as Pfizer continues to invest heavily in AI across its business. The company has made significant strides in using AI for drug development, partnering with organizations like CytoReason and the Research Center for Molecular Medicine (CeMM) to drive AI-driven drug discovery. In clinical trials, AI has played a crucial role in accelerating data analysis, notably contributing to the rapid development of Pfizer’s COVID-19 treatment, PAXLOVID.
Moreover, Pfizer’s use of AI in supply chain management has proven vital during the COVID-19 vaccine rollout, enabling the company to predict and manage supply chain issues effectively. By optimizing production processes and reducing cycle times, Pfizer has increased efficiency and capacity, ensuring that its life-saving vaccines reach patients swiftly.
Pfizer’s recent launch of PfizerForAll, a user-friendly digital platform, is a clear example of the company’s dedication to making healthcare more accessible and personalized. Designed to bring together essential health resources in one place, PfizerForAll aims to simplify the way millions of Americans manage their health and wellness.
